



Vienna, September 08, 2021

Dear Colleagues in IBD,

In order to keep building on the contact that was established the previous years and aiming to foster collaboration among IBD National Study Groups in the framework of clinical studies further, **the Clinical Research Committee of ECCO (ClinCom) is once again organising a National Study Group meeting at the next 17<sup>th</sup> Congress of ECCO in Vienna.**

- Date: February 16, 2022 (Wednesday)
- Time: 17:15 – 19:15
- Place: Messe Wien, Vienna (Austria)

During the meeting, slots are kept for **the presentation of new study project proposals**. ClinCom can help you establishing a network, and performing a critical review of your studies to optimize study protocols and to help avoid redundant or scientifically questionable research efforts.

The assessment of a clinical research protocol encompasses a **2-stage process**.

**1<sup>st</sup> stage:**

During the first stage, applicants are called upon to provide a study synopsis including background, design, objectives, outcome parameters, major inclusion and exclusion criteria, statistics, and co-variables not exceeding 4 pages.

The project will be reviewed by ClinCom and we will come back to you either supporting or declining the presentation at the IBD National Study Group Meeting at the 17<sup>th</sup> Congress of ECCO.

Should you wish to have your projects discussed at the 7<sup>th</sup> National Study Group meeting, **you are kindly invited to send your project proposals using the first stage's template of ECCO by October 22, 2021. Please download the first stage's template [here](#) and send it back to the following email address: [ecco@ecco-ibd.eu](mailto:ecco@ecco-ibd.eu)**

**2<sup>nd</sup> stage:**

Beginning of 2022, the principal investigators who will present their study projects at the IBD National Study Group Meeting will be invited to submit a full protocol of their studies using an ECCO second stage's template.

**Governing Board**

*President*

Laurent Peyrin-Biroulet  
France

*President-Elect*

Britta Siegmund  
Germany

*Past-President*

Silvio Danese  
Italy

*Secretary*

Alessandro Armuzzi  
Italy

*Treasurer*

Janneke van der Woude  
The Netherlands

*Education Officer*

Fernando Magro  
Portugal

*Scientific Officer*

Ailsa Hart  
United Kingdom

*ECCO Office*

Ungargasse 6/13  
1030 Vienna, Austria

Tel. +43-(0)1-710 22 42  
Fax +43-(0)1-710 22 42-001  
E-Mail [ecco@ecco-ibd.eu](mailto:ecco@ecco-ibd.eu)  
Url [www.ecco-ibd.eu](http://www.ecco-ibd.eu)

SWIFT GIBAAWWXXX  
IBAN AT5720111 28748039100

ATU 63674955  
Austrian Register of Associations  
N° 468755685  
DPR Number: N°4003204



European  
Crohn's and Colitis  
Organisation

#### Governing Board

*President*

Laurent Peyrin-Biroulet  
France

*President-Elect*

Britta Siegmund  
Germany

*Past-President*

Silvio Danese  
Italy

*Secretary*

Alessandro Armuzzi  
Italy

*Treasurer*

Janneke van der Woude  
The Netherlands

*Education Officer*

Fernando Magro  
Portugal

*Scientific Officer*

Ailsa Hart  
United Kingdom

*ECCO Office*

Ungargasse 6/13  
1030 Vienna, Austria

Tel. +43-(0)1-710 22 42  
Fax +43-(0)1-710 22 42-001  
E-Mail [ecco@ecco-ibd.eu](mailto:ecco@ecco-ibd.eu)  
Url [www.ecco-ibd.eu](http://www.ecco-ibd.eu)

SWIFT GIBAATWWXXX  
IBAN AT5720111 28748039100

ATU 63674955  
Austrian Register of Associations  
N° 468755685  
DPR Number: N°4003204

#### Application criteria:

If you are interested in submitting a study proposal and presenting it at the 7<sup>th</sup> IBD National Study Group meeting, please take into consideration the following information:

- Applicants need to be individual ECCO Members (=ECCO Members 2022).
- The study should be multicentric, executed predominantly in Europe.
- It should be a study with a simple and practical design, in which the great advantage of sharing with the IBD National Study Groups is recruiting a high number of patients. In this sense, ideally the study should be observational, non-interventional and retrospective. Randomized Clinical Trials are not recommended as these studies generally require a highly complex design.
- Proposed by an independent researcher.
- The investigation must be independent of the industry interests.

**FINAL NOTE:** ECCO is happy to facilitate the IBD National Study Group Meeting at the ECCO Congress to enhance international collaboration. The main contribution of ClinCom to these projects is scientific review and dissemination. However, ECCO does not provide financial or logistical support to these studies. Review of project protocols by ClinCom does not represent an ECCO endorsement for the projects.

We look forward to receiving your proposals!

Best regards,

The Clinical Research Committee

Krisztina Gecse (Chair)

Laurent Beaugerie

Peter Bossuyt

Uri Kopylov

Shaji Sebastian